This article examines the stability of symptoms, syndromes, and diagnoses of specific anxiety and depressive disorders, as well as diagnostic shifts from one syndrome to another over time. Using retrospective and longitudinal prospective data from the baseline and first follow-up investigation (19.7 months later) of the Early Developmental Stages of Psychopathology Study (EDSP), we focus on establishing stability measures for early stages of mental disorders in a community sample of adolescents aged 14 to 17 years at baseline. The results are as follows: (1) Although only about 30% developed a full-blown DSM-IV disorder, psychopathological syndromes are widespread in adolescents: 15% of the population aged 14 to 17 at baseline were not affected by at least some clinically relevant symptoms of mental disorders either throughout their previous life or throughout the follow-up period. (2) The likelihood of staying free of symptoms and threshold disorders during follow-up was highest among subjects who were completely well at baseline. The probability of a positive outcome decreased as a function of severity of baseline diagnostic status. (3) There was a considerable degree of fluctuation not only in the diagnostic status and severity of specific disorders, but also in terms of complete remissions and shifts from one syndrome and disorder to another. (4) Anxiety disorders, overall, slightly differ with regard to the persistence and stability of the diagnostic status from depressive disorders. (5) However, there were remarkable differences between specific types of anxiety and depressive disorders. Consistent with other longitudinal epidemiological studies in the general population, this study finds that the syndromes and diagnoses of mental disorders have a strong tendency to wax and wane over time in this age group.

Aims: To assess effectiveness and economic benefit of the psychological treatment of anxiety disorders in order to compare them with the consumed resources of the treatment. Methods: Assessment of specific and non-specific symptoms and impairments in N=493 anxiety patients (DSM-IV) receiving cognitive behavior therapy pre, post, and one year after treatment with various measures. Additional analyses of costs of the treatment and the benefits due to reduced work disability and health care utilization after therapy (including a pilot study using a willingness-to-pay approach). The treatment setting can be characterised as clinically typical for everyday practice. Core results: a) effectiveness: Effect sizes ranged from 0.9 to 1.9. All improvements were significant and lasted until 1-year-follow-up. Rates of clinically significant therapy success ranged from 63% to 79% depending on outcome measure and success criteria. b) cost-effectiveness analysis: Cost-effectiveness-indices ranged from DM 8338.- to DM 10456.- for one successful treatment (average costs taking also the costs of unsuccessful treatments into account). c) cost-benefit-analysis: Cost reduction in the year after therapy was remarkable (inpatient costs about 25%, other cost factors 87%-100%), resulting in a benefit of DM 3026.- per patient and a cost-benefit-ratio of 1:0.58 in the first year after treatment. Assuming that the improvements are stable, the cost-benefit-ratio after five years would be estimated as 1:2.63. Discussion: The present study shows exemplarily for CBT of anxiety disorders that modern psychotherapy can produce remarkable results at reasonable costs. Furthermore, clinical-psychological treatment methods show an additional economic benefit. Clinical Psychology can benefit from focusing not only the promising developments in classification, etiology, and treatment but also taking over the cost perspective (which is relatively new in scientific evaluation of psychotherapy). (Appendix: Cost-Benefit-Calculator.htm; 8,97 KB -- Usage: Referat Informationsvermittlung/ SLUB) / Fragestellungen: Ermittlung von Effektivität und monetärem Nutzen psychologischer Behandlung von Angststörungen, die dann den für die Therapie aufgewendeten Ressourcen gegenübergestellt werden. Methoden: N=493 Patienten mit Angststörungen (DSM-IV), die eine ambulante störungsspezifische kognitive Verhaltenstherapie absolviert haben, wurden prä, post und zur 1-Jahres-Katamnese untersucht. Das Spektrum der Erhebungen umfasste störungsspezifische und störungsübergreifende Symptombelastung und Beeinträchtigungen in verschiedenen Lebensbereichen, sowie eine globale Therapieerfolgseinschätzung von Patienten und Therapeuten. In einer zweiten Studie wurden zusätzlich an einer Teilstichprobe Kosten-Nutzen-Aspekte untersucht (Einsparungen durch Reduktion von Gesundheitsleistungen und Arbeitsunfähigkeit; außerdem Pilotstudie zu willingness-to-pay-Ansatz). Das Behandlungssetting der Studie ist charakterisiert durch klinisch relevante Rahmenbedingungen und Praxisnähe. Zentrale Ergebnisse: a) Effektivität: Die Effektstärken reichten in Abhängigkeit von der Meßmethode von 0.9 bis 1.9. Die Verbesserungen waren durchgängig signifikant und blieben bis zur 1-Jahres-Katamnese stabil. Die Raten klinisch bedeutsamer Besserungen betrugen 63% - 79% in Abhängigkeit von Mess- und Auswertungsmethode. b) Kosten-Effektivitäts-Analyse: Die Kosten-Effektivitätivitäts-Indices betrugen DM 8338.- bis DM 10456.- (dieser Index gibt an, was eine erfolgreiche Behandlung durchschnittlich kostet, also unter Einbezug der nicht erfolgreichen Behandlungen in die Gesamtkosten). c) Kosten-Nutzen-Analyse: Im Jahr nach Therapie reduzierten sich die Kostenfaktoren der Störungen vor Therapie beträchtlich (stationäre Kosten um 25%, restliche Kostenfaktoren 87% - 100%). Die dadurch erzielten Einsparungen betrugen durchschnittlich DM 3026.- (Kosten-Nutzen-Verhältnis im ersten Jahr: 1 : 0.58). Unter der Annahme, dass die Auswirkungen der Therapie auch über die 1-Jahres-Katamnese hinaus stabil bleiben, kann man abschätzen, dass sich die Therapie innerhalb des zweiten Jahres amortisiert und das Kosten-Nutzen-Verhältnis nach fünf Jahren (diskontiert) 1 : 2.63 beträgt. Diskussion: Wie in dieser Arbeit anhand der kognitiven Verhaltenstherapie für Angststörungen gezeigt wird, kann moderne Psychotherapie bei vertretbarem Aufwand beachtliche Erfolge verbuchen. Klinisch-psychologische Behandlungsmethoden sind darüber hinaus auch wirtschaftlich, derart, dass sie über den reinen Behandlungserfolg hinaus zu Kosteneinsparungen beitragen könnten. Es ist erstaunlich, dass die Kosten-Perspektive der wissenschaftlichen Bewertung von Psychotherapie noch recht neu ist. Die Klinische Psychologie kann davon profitieren, diese Dimension (neben den beachtlichen Erkenntnisfortschritten in bezug auf Klassifikation, Ätiologie, Verlaufsforschung und Behandlungsverfahren) mehr herauszustellen. (Anlage: Cost-Benefit-Calculator.htm; 8,97 KB -- Nutzung: Referat Informationsvermittlung der SLUB)

Fear is an innate emotion and an adaptive response to provide protection from potential harm. When fear is excessive and out of proportion in relation to the confronted situation, it can lead to the development of an anxiety disorder. Many individuals feel anxious at some point, but not all experience clinical anxiety or meet the diagnostic criteria of an anxiety disorder. Still, anxiety disorders are the most prevalent form of psychiatric disorder in the general population. More often than not people suffering from one anxiety disorder also present other psychiatric conditions. As of today, cognitive and behavioural treatments have been tested and found to positively affect anxiety disorders, making them the treatment of choice. Nevertheless, many patients do not seek or receive adequate treatment. One common critique of the research trials from which the recommendations for treatments stem is the use of a single protocol targeting only one diagnosis. This is because many people suffer from comorbidities. Another problem connected to the recommendation that cognitive behavioural therapy (CBT) should be the treatment of choice for anxiety disorders is the lack of therapists with adequate training. One possible way of dealing both with the shortcoming of therapists and making CBT more accessible is the use of the Internet. Internet-based CBT (ICBT) has been tested in numerous trials during the last 15 years, showing positive outcomes for a large variety of disorders. Many ICBT trials also make use of a single protocol. Another way of dealing with comorbidities might be to tailor the treatment to let characteristics and preferences of the patient guide the design of the protocol. Little is known about possible effects of tailoring the ICBT, the effects of therapeutic relationships in ICBT, and the effectiveness and cost-effectiveness of these treatments. This thesis is based on three studies on two separate randomized controlled trials (RCTs) using the same set of modules accessible for the tailored protocol. Study I was an RCT investigating treatment effects up to two-year after completion, showing favourable outcomes of the treatment in a self-recruited sample at all measure points. Study II was a secondary analysis exploring possible relations between working alliance and treatment outcome for participants in the treatment group recruited for Study I indicating that working alliance predict outcome in this tailored treatment. The second RCT was an effectiveness trial (Study III) analysing treatment effects and cost-effectiveness of the treatment up to one year post treatment in a primary-care population. This study showed positive treatment effects both regarding symptom reduction and cost-effectiveness, and that effects were sustained at one year post treatment. Conclusions drawn from these studies are that individually tailored ICBT seems to be a feasible approach for patients with anxiety disorders regardless of comorbidities, and a responsible choice in terms of societal costs. / Rädsla är en medfödd känsla och en adaptiv respons för att skydda organismen från potentiell skada. När rädslan blir överdriven och oproportionerlig i relation till den konfronterade situationen, kan det leda till utvecklandet av ångestsyndrom. Många personer upplever någon gång ångest, men inte alla upplever klinisk ångest eller uppfyller de diagnostiska kriterierna för något ångestsyndrom. Trots detta är ångest det vanligaste psykiatriska tillståndet i befolkningen i stort och oftast uppfyller personer som lider av ett ångestsyndrom även andra  psykiatriska tillstånd. Till dags dato har både kognitiva och beteendeinriktade behandlingar testats och visat sig verksamma vid ångestproblem, vilket gjort dem till de behandlingar som rekommenderas för dessa tillstånd. Trots god effekt av behandling söker många patienter ändå inte hjälp, alternativt erhåller inte adekvat behandling. En vanlig kritik mot den forskning från vilka behandlingsrekommendationerna för ångestsyndrom stammar är att många använt en manual eller ett protokoll som riktar sig mot bara en diagnos. Detta på grund av den stora komorbiditeten. Ett annat problem kopplat till rekommendationerna att kognitiv beteendeterapi (KBT) ska vara förstahandsval vid behandling av ångest är bristen på behandlare med adekvat utbildning. Ett möjligt sätt att göra KBT mer tillgängligt är att använda Internet. Internet- förmedlad KBT (IKBT) har prövats i ett stort antal studier de senaste 15 åren dessa har visat positiva resultat vid ett stort antal psykiatriska tillstånd. Flertalet av dessa studier har dock använt ett enda behandlingsprotokoll. En annan möjlighet att hantera komorbiditet kan vara att skräddarsy behandlingen för att låta patientens egenskaper och preferenser vara med och styra utformningen av behandlingsprotokollet. Möjliga effekter av att skräddarsy IKBT är relativt lite undersökt, likaså effekterna av terapeutiska relationer i IKBT samt klinisk effektivitet och kostnadseffektiviteten för dessa behandlingar. Denna avhandling bygger på tre studier från två randomiserade kontrollerade studier med samma uppsättning av moduler tillgängliga för att skräddarsy behandlingsprotokollen. I Studie I undersöktes behandlingseffekter upp till två år efter avslutad behandling i en självrekryterad grupp patienter. Studie II var en sekundäranalys av behandlingsgruppen från Studie I där eventuella samband mellan arbetsallians och behandlingsresultat undersöktes. Den andra randomiserade kontrollerade studien var en prövning av huruvida denna behandling var effektiv för en klinisk population (Studie III) rekryterad via primärvården. Förutom behandlingseffekter undersöktes även kostnadseffektiviteten upp till ett år efter behandlingsavslut. De slutsatser som dras utifrån dessa studier är att skräddarsydd IKBT verkar vara en framkomlig väg för patienter med ångest oavsett komorbiditet, att arbetsalliansen kan vara en faktor som påverkar utfallet, samt att det är ett ansvarsfullt val vad gäller samhälleliga kostnader.

Hintergrund: Seit Einführung des DSM-III-R wird die Frage, ob Agoraphobie eine Komplikation der Panikstörung ist oder eine eigenständige Diagnose darstellt, und deshalb gleichberechtigt mit der Sozialen und Spezifischen Phobie der Gruppe der Phobien zugeordnet werden sollte, kontrovers diskutiert. Die zwei Positionen in dieser Kontroverse finden ihren Ausdruck im unterschiedlichen Gebrauch hierarchischer Regeln in den gegenwärtig gebräuchlichen Klassifikationssystemen für psychische Störungen, dem Diagnostic and Statistical Manual of Mental Disorders (DSM) und der International Classification of Diseases (ICD). Die empirischen Belege für die Validität solcher hierarchischer Regeln sind allerdings bisher unbefriedigend. Ziel der vorliegenden Arbeit ist es deshalb, ohne Berücksichtigung der gültigen Hierarchieregeln das natürliche Auftreten von Agoraphobie und Panikstörung zu untersuchen und damit einen Beitrag zum Fortschritt in der oben genannten Kontroverse zu leisten. Methoden: Die Analysen der vorliegenden Arbeit beruhen auf Daten der Early Developmental Stages of Psychopathology (EDSP) Studie. Bei der EDSP handelt es sich um eine prospektiv-longitudinale Studie an einer bevölkerungsrepräsentativen Kohorte von 3021 Jugendlichen und jungen Erwachsenen im Alter von 14 bis 24 Jahren aus München und Umgebung. Die Studienteilnehmer wurden in einem 10-Jahres-Follow-up mit bis zu vier Erhebungszeitpunkten mit der computerisierten Version des Münchener Composite International Diagnostic Interview (DIA-X/M-CIDI) untersucht. Das M-CIDI gestattet es, Panik- und Agoraphobiesyndrome unabhängig von hierarchischen Regeln zu erheben. Risiko- und Vulnerabilitätsfaktoren wurden anhand von Fragebögen erhoben. Die Studie umfasst darüber hinaus zwei familiengenetische Untersuchungen, in deren Rahmen auch die Eltern der Studienprobanden interviewt wurden. Die direkten Elterninterviews wurden durch Informationen der Studienprobanden über ihre Eltern ergänzt. Ergebnisse: Studie 1: Agoraphobia and Panic: Prospective-longitudinal Relations Suggest a Rethinking of Diagnostic Concepts Die Lifetimeinzidenz bis zum Alter von 34 Jahren betrug 9.4% für Panikattacken, 3.4% für Panikstörung (mit und ohne Agoraphobie) und 5.3% für Agoraphobie. Unter den Personen mit Agoraphobie berichteten 51% keine lifetime Panikattacken. Die Inzidenzmuster der drei Syndrome unterschieden sich bezüglich Erstauftrittsalter, Risikoverlauf und Geschlechtseffekten. Zeitlich vorausgehende Panikattacken und Panikstörung waren assoziiert mit einem Risiko für zeitlich nachfolgende Agoraphobie (Panikattacken: OR=26.7, 95% KI=17.2-41.4; Panikstörung: OR=62.5, 95% KI=38.5-101.2). In streng prospektiven Analysen waren Panikattacken/Panikstörung zur Baseline mit Panikattacken/Panikstörung im Follow-up assoziiert und Agoraphobie zur Baseline mit Agoraphobie im Follow-up. Panikattacken, Panikstörung und Agoraphobie zur Baseline hatten niedrige Remissionsraten (0-23%). Alle diagnostischer Gruppen waren bis auf Panikstörung ohne Agoraphobie mit anderen Angststörungen im Follow-up assoziiert. Panikstörung mit Agoraphobie und Agoraphobie mit Panikattacken zur Baseline zeigten höhere Assoziationen mit Komplikationen wie Beeinträchtigung, Komorbidität und Hilfesuchverhalten als Panikstörung ohne Agoraphobie und Agoraphobie ohne Panikattacken. Personen mit Panikattacken/Panikstörung suchten häufiger ärztliche Hilfe als Personen mit Agoraphobie ohne Panikattacken. Besonders ausgeprägt war Hilfesuchverhalten bei Personen mit Panikstörung mit Agoraphobie. Studie 2: Differential Familial Liability of Panic Disorder and Agoraphobia Panikattacken, Panikstörung und Agoraphobie der Eltern waren assoziiert mit denselben Syndromen der Kinder. Bei separater Untersuchung der Störungen wurde für Agoraphobie ohne Panikstörung keine Assoziation zwischen Eltern und Kindern beobachtet. Elterliche Panikstörung ohne Agoraphobie war nicht mit Panikstörung ohne Agoraphobie bei den Kindern, aber mit Panikstörung mit Agoraphobie (OR=3.9; 95% KI=1.6-9.4) assoziiert. Panikstörung mit Agoraphobie der Eltern war mit Agoraphobie ohne Panikstörung (OR=3.3; 95% KI=1.01-11.1) und mit Panikstörung ohne/mit Agoraphobie bei den Kindern assoziiert (ohne Agoraphobie: OR=4.2; 95% KI=1.2-13.7; mit Agoraphobie: OR=4.9; 95% KI=1.8-12.5). Bei Kontrolle nach anderen Angststörungen blieb nur die Assoziation von Panikstörung mit Agoraphobie bei Eltern und Kindern stabil. Es fanden sich keine Hinweise auf Assoziationen zwischen Panikstörung oder Agoraphobie der Eltern mit einem früheren Erstauftrittsalter der kindlichen Störung. Studie 3: Pathways into panic and phobias Der Komorbidität von Panikstörung, Agoraphobie und Spezifischen Phobien lag eine Vier-Klassen-Struktur zugrunde. Die Klassen konnten beschrieben werden als „sehr niedriges Risiko für Angststörungen“, „niedriges Risiko für Spezifische Phobien“, „moderates Risiko für Agoraphobie und Panikstörung“ und „hohes Risiko für Angststörungen“. Die letztgenannte Klasse zeichnete sich vor allem durch das Vorliegen von Agoraphobie und dem Situativen Subtypus der Spezifischen Phobie aus. Die drei letztgenannten Risikoklassen waren assoziiert mit weiblichem Geschlecht, Behavioral Inhibition, Harm Avoidance, überbehütendem und abweisendem Elternverhalten, elterlichen Angst- und depressiven Störungen, sowie Trennungs- und traumatischen Erlebnissen in der Kindheit. Die Klasse „hohes Risiko für Angststörungen“ war assoziiert mit elterlicher Spezifischer Phobie (OR=5.0, 95% KI=1.9-12.8) und postnatalen Komplikationen (OR=7.4; 95% KI=2.4-22.9). Sie unterschied sich darin von allen anderen Risikogruppen. Die Klasse „moderates Risiko für Agoraphobie und Panikstörung“ war assoziiert mit Trennungsangst in der Kindheit (OR=6.3; 95% KI=2.0-19.8), einem emotional kühlen elterlichen Erziehungsstil (OR=0.7; 95% KI=0.6-0.9) und einer geringen Wahrscheinlichkeit für postnatale Komplikationen (OR=0.3; 95% KI=0.1-0.9). Schlussfolgerungen: Unterschiede hinsichtlich des Inzidenzmusters, des Verlaufs und der Korrelate zwischen Panik- und Agoraphobiesyndromen zeigen, dass Agoraphobie getrennt von Paniksyndromen existiert und eine klinisch relevante Störung darstellt. Dabei hatte die Hälfte der Personen mit Agoraphobie keine Panikattacke erlebt und bliebe gemäß DSM-Kriterien undiagnostiziert. Ergebnisse der Familienstudie zeigen, dass Befunde zur familiären Aggregation von Panikstörung und Agoraphobie bisher von angewandten hierarchischen Diagnoseregeln abhängig waren. Ohne Anwendung hierarchischer Kriterien aggregiert Agoraphobie ohne Panikstörung nicht in Familien und die familiäre Aggregation von Panikstörung hängt davon ab, ob bei den Kindern komorbide Agoraphobie oder andere Angststörungen vorliegen. Die Ergebnisse der Latent Class Analysen lassen vermuten, dass Panikstörung, Agoraphobie und Spezifische Phobien sich im Rahmen von Vulnerabilitätsklassen entwickeln, auf zwei pathogene Mechanismen der Agoraphobie hinweisen: Agoraphobie kann sich entweder in naher Verwandtschaft zur Panikstörung, oder zum Situativen Subtypus der Spezifischen Phobie entwickeln. Spezifische Zusammenhänge dieser Risikoklassen mit untersuchten Vulnerabilitätsfaktoren stützen die Hypothese einer unterschiedlichen Ätiopathogenese der Agoraphobie. Zusammenfassend zeigen die vorliegenden Daten, dass Panikattacken und Panikstörung weder eine notwendige noch eine hinreichende Bedingung für Agoraphobie sind, und die derzeit gültige Klassifikation die Untersuchung der Agoraphobie behindert. Die aktuell in Arbeit befindliche Revision des DSM sollte im Sinne einer beschreibenden, durch empirische Daten gestützten Diagnostik das Konzept der Agoraphobie überarbeiten und von einer Diagnostik im Sinne einer nosologischen Kontroverse abrücken.

Σήμερα, βρισκόμαστε ήδη στο στάδιο μετάβασης από τις παραδοσιακές επιτραπέζιες υπολογιστικές τεχνολογίες στα διάχυτα (ubiquitous) υπολογιστικά περιβάλλοντα που θα μας υποστηρίζουν σχεδόν σε κάθε καθημερινή μας λειτουργία ή δραστηριότητα. Παράλληλα, υπάρχει μία αυξανόμενη τάση για τοποθέτηση του χρήστη στο κέντρο των υπηρεσιών. Αυτό σημαίνει ότι οι υπηρεσίες θα προσαρμόζονται με βάση το στενό και ευρύτερο περιβάλλον διαβίωσης (context), τις ανάγκες και τις προτιμήσεις των χρηστών. Δύο από τις βασικότερες έννοιες στις οποίες βασίζεται η προσφορά διάχυτων εξατομικευμένων υπηρεσιών είναι η γνώση πλαισίου (context awareness) και η μοντελοποίηση χρηστών (user modeling). Η έλευση του διάχυτου υπολογισμού και η χρησιμοποίηση της διάχυτης μοντελοποίησης χρηστών (ubiquitous user modeling) έχει δημιουργήσει νέες προσδοκίες και προκλήσεις για την παροχή εξατομικευμένων υπηρεσιών σε πολλούς τομείς εφαρμογών μεταξύ των οποίων είναι και ο τομέας της υγείας. Η ιατρική αντιμετώπιση αλλάζει πλέον κατεύθυνση και γίνεται προστατευτική, προληπτική και εύκολα προσεγγίσιμη (π.χ. στη δουλειά, στο σπίτι, κλπ.), συνοδευόμενη από συνεχή και εμμένουσα παροχή υψηλής ποιότητας εξατομικευμένης ιατρικής συμβουλής και υποστήριξης. Οι σύγχρονες ιατρικές υπηρεσίες αναμένονται να είναι διαθέσιμες κάθε στιγμή, 7 ημέρες την εβδομάδα και να παρέχονται με έναν εξατομικευμένο τρόπο ώστε να απευθύνονται στις ιδιαίτερες ανάγκες και απαιτήσεις κάθε ατόμου. Η παρούσα διατριβή πραγματεύεται μία μεθοδολογία παροχής διάχυτων υπηρεσιών σε εξελιγμένα τηλεπικοινωνιακά δίκτυα που συνδυάζει τη γνώση πλαισίου, τη μοντελοποίηση χρηστών και τα κοινωνικά δίκτυα (social networks). Η μεθοδολογία αυτή εφαρμόστηκε στον ιατρικό χώρο και ειδικότερα στις διαταραχές άγχους. Πιο συγκεκριμένα, στη διατριβή καθορίστηκαν πλήρως οι παράμετροι πλαισίου που σχετίζονται άμεσα με τις διαταραχές άγχους και προτάθηκε ένα μοντέλο πλαισίου που βασίζεται σε οντολογίες. Επίσης, μελετήθηκε η δομή και οι τεχνικές κατασκευής και ανανέωσης των μοντέλων χρηστών, ενώ μελετήθηκε η χρήση των κοινωνικών δικτύων για την παροχή ιατρικής φροντίδας και οι ρόλοι των μελών τους στις διαταραχές άγχους. Τέλος, προτάθηκε η αρχιτεκτονική ενός συστήματος γνώσης πλαισίου που ενσωματώνει τις ανωτέρω τεχνολογίες, τμήμα του οποίου αναπτύχθηκε, υλοποιήθηκε και αξιολογήθηκε από επαγγελματίες ιατρούς. Κατά την εφαρμογή της παραπάνω μεθοδολογίας στις διαταραχές άγχους αναπτύχθηκε η εφαρμογή PerMed που αποτελεί ένα εργαλείο αρχειοθέτησης και επεξεργασίας των προσωπικών πληροφοριών των ασθενών και τέσσερις υπηρεσίες που στοχεύουν στην υποστήριξη της θεραπείας των διαταραχών άγχους. Οι τρεις εστιάζουν στην ανακάλυψη πιθανών συσχετίσεων στα δεδομένα πλαισίου, ενώ η τέταρτη στοχεύει στην πρόβλεψη του άγχους που θα παρουσιάσει ένας ασθενής σε ένα δεδομένο πλαίσιο. Τα σχόλια που λάβαμε από επαγγελματίες ψυχιάτρους είναι αρκετά ενθαρρυντικά και ευελπιστούμε ότι η προτεινόμενη προσέγγιση θα αποτελέσει ένα ισχυρό εργαλείο υποστήριξης της θεραπείας των διαταραχών άγχους. / Today, we are already on the transition from the traditional desktop-based computing technologies towards ubiquitous computing environments that will enfold us in almost all our daily situations and activities. Simultaneously, there exists an increased tendency of putting the user into the center of service delivery. This means that the services in the ubiquitous environments should be adapted to the context, the needs and the preferences of users. Two of the key-concepts, based on which the delivery of ubiquitous personalized services is realized, are context-awareness and user modeling. The emergence of ubiquitous computing and ubiquitous user modeling has created new expectations and challenges for the delivery of personalized services in a considerable amount of application domains, among which is the healthcare domain. Healthcare provision changes direction becoming protective, proactive and more reachable (e.g. at home or at work), accompanied by continuous and persistent provision of personalized high-quality health advice and assistance. Modern healthcare services are expected to be available around the clock, seven days a week and delivered in a personalized manner addressing the specific needs and preferences of each individual. The present dissertation presents a methodology of providing ubiquitous services at advanced telecommunication networks, which combines context-awareness, user modeling and social networks. This methodology was implemented in the healthcare domain and more specifically in anxiety disorders. In particular, in this dissertation, the contextual aspects that are directly associated with anxiety disorders were defined and an ontology-based context model was proposed. In addition, the user models’ structure was determined and the techniques for the processing of their content were developed. Furthermore, the use of social networks in anxiety disorders and the role of their members were studied. Finally, the architecture of a context-aware system that integrates all the above technologies was proposed, a part of which was developed, implemented and evaluated by professional psychiatrists. During the implementation of the proposed methodology in anxiety disorders, the PerMed application that provides medical experts with a tool for archiving and processing the patient’s personal data and four treatment supportive services were developed. The three of them focus on the discovery of possible associations between the patient’s contextual data and the last service aims at predicting the stress level a patient might suffer from, in a given context. The feedback received from expertized psychiatrists was very encouraging and we hope that the proposed approach will constitute a powerful treatment supportive tool for anxiety disorders.

Introdução: A privação de sono (PdS) tem sido utilizada como um estratégia alternativa para o tratamento do Transtorno Depressivo Maior (TDM), contudo sua eficácia e efetividade carecem de estudos homogêneos e de bom delinemento para dar um grau de evidência científica para seu uso na prática diária. Assim sendo, desde a primeira publicação, em 1971, num relato de caso de um paciente com TDM grave tipo melancólico, por Plug e Tölle, o mesmo estava assintomático no dia seguinte à privação total de sono. Contudo, na noite seguinte de sono seus sintomas depressivos retornaram. Nestes quase 40 anos desde esta publicação houve dezenas de estudos em sua maioria relatos de caso, série de casos ou até estudos abertos só que misturando pacientes com TDM com Depressão Bipolar sem mesmo distinguir se tipo I ou II. A cafeína com seu efeito estimulador poderia ser uma alternativa para facilitar a privação de sono. No entanto, não há dados sobre o sua potencial influência no efeito antidepressivo da PdS. O objetivo deste estudo é avaliar o efeito da cafeína na PdS em pacientes deprimidos unipolares moderados a graves não psicóticos. Métodos: Ensaio Clínico randomizado, duplo cego, cruzado, comparando cafeína contra placebo em pacientes deprimidos moderados a graves submetidos à privação total de sono (PdS). Os pacientes foram avaliados por itens da escala de Lader, HAMD- 6 itens, CGI Severidade e Melhora Global. Resultados: Foram avaliados 20 pacientes. Os pacientes que usaram cafeína mantiveram o mesmo escore de energia pré e pós-privação de sono (item energético-letárgico da escala de Lader) enquanto os do grupo placebo diminuíram o escore de energia pós-privação de sono. (p = 0,0045). Não houve diferença entre o grupo cafeína e placebo nos demais itens da escala de Lader. Conclusão: O uso combinado de cafeína e PdS pode ser uma estratégia útil para manter os pacientes mais acordados sem o prejuízo do cansaço da PdS em pacientes ambulatoriais deprimidos. Contudo, mais estudos envolvendo pacientes que tenham 10 respondido à PdS são necessários para verificar se a cafeína também não interfere nos resultados deste grupo. / Introduction: Sleep deprivation (SD) has been used as an alternative approach to treat major depressive disorder (MDD), however the efficacy and the effectiveness needs studies with homogeneity and better delineament to strengthen the evidence based medicine to the use in the practical daily use. Besides, since the 1° puplication in 1971 of a case report, by Plug and Tölle, in that one patient with severe melancholic depressive disorder achieved remission in the next day after a total sleep deprivation. However his depressive sintomtology was back after the next night of sleep. Since this almost 40 years, a lot of papers were puplished, and the majority where case report, case reports and open trials with patients with MDD, bipolar depression without make difference between tipe I or II. Caffeine, due to its stimulating effect, could be an alternative to promote sleep deprivation. However, there are no data about its potential influence on the antidepressive effect of SD. The objective of this study is to assess the effect of caffeine on SD in non-psychotic patients with moderate to severe unipolar depression. Methods: Randomized, double-blind, crossover clinical trial comparing caffeine and placebo in moderate to severe depressed patients who underwent total sleep deprivation (SD). The patients were assessed with items of the Bond-Lader Scale, the 6-item Hamilton Depression Rating Scale (HAMD-6), and the Clinical Global Impression (CGI)-Severity/Improvement. Results: Twenty patients participated in this study. The patients who consumed caffeine presented the same score of energy before and after sleep deprivation (lethargicenergetic item of the Bond-Lader scale), while the patients in the placebo group had a reduced score of energy after sleep deprivation (p = 0.0045). There was no difference between the caffeine and placebo groups in the other items of the Bond-Lader scale. Conclusion: The combined use of caffeine and SD can be a useful strategy to keep the 12 patient awake without impairing the effect of SD on depressed outpatients. However, further studies involving patients who have responded to SD are needed in order to verify if caffeine also does not interfere with the results in this group.

Introdução: A privação de sono (PdS) tem sido utilizada como um estratégia alternativa para o tratamento do Transtorno Depressivo Maior (TDM), contudo sua eficácia e efetividade carecem de estudos homogêneos e de bom delinemento para dar um grau de evidência científica para seu uso na prática diária. Assim sendo, desde a primeira publicação, em 1971, num relato de caso de um paciente com TDM grave tipo melancólico, por Plug e Tölle, o mesmo estava assintomático no dia seguinte à privação total de sono. Contudo, na noite seguinte de sono seus sintomas depressivos retornaram. Nestes quase 40 anos desde esta publicação houve dezenas de estudos em sua maioria relatos de caso, série de casos ou até estudos abertos só que misturando pacientes com TDM com Depressão Bipolar sem mesmo distinguir se tipo I ou II. A cafeína com seu efeito estimulador poderia ser uma alternativa para facilitar a privação de sono. No entanto, não há dados sobre o sua potencial influência no efeito antidepressivo da PdS. O objetivo deste estudo é avaliar o efeito da cafeína na PdS em pacientes deprimidos unipolares moderados a graves não psicóticos. Métodos: Ensaio Clínico randomizado, duplo cego, cruzado, comparando cafeína contra placebo em pacientes deprimidos moderados a graves submetidos à privação total de sono (PdS). Os pacientes foram avaliados por itens da escala de Lader, HAMD- 6 itens, CGI Severidade e Melhora Global. Resultados: Foram avaliados 20 pacientes. Os pacientes que usaram cafeína mantiveram o mesmo escore de energia pré e pós-privação de sono (item energético-letárgico da escala de Lader) enquanto os do grupo placebo diminuíram o escore de energia pós-privação de sono. (p = 0,0045). Não houve diferença entre o grupo cafeína e placebo nos demais itens da escala de Lader. Conclusão: O uso combinado de cafeína e PdS pode ser uma estratégia útil para manter os pacientes mais acordados sem o prejuízo do cansaço da PdS em pacientes ambulatoriais deprimidos. Contudo, mais estudos envolvendo pacientes que tenham 10 respondido à PdS são necessários para verificar se a cafeína também não interfere nos resultados deste grupo. / Introduction: Sleep deprivation (SD) has been used as an alternative approach to treat major depressive disorder (MDD), however the efficacy and the effectiveness needs studies with homogeneity and better delineament to strengthen the evidence based medicine to the use in the practical daily use. Besides, since the 1° puplication in 1971 of a case report, by Plug and Tölle, in that one patient with severe melancholic depressive disorder achieved remission in the next day after a total sleep deprivation. However his depressive sintomtology was back after the next night of sleep. Since this almost 40 years, a lot of papers were puplished, and the majority where case report, case reports and open trials with patients with MDD, bipolar depression without make difference between tipe I or II. Caffeine, due to its stimulating effect, could be an alternative to promote sleep deprivation. However, there are no data about its potential influence on the antidepressive effect of SD. The objective of this study is to assess the effect of caffeine on SD in non-psychotic patients with moderate to severe unipolar depression. Methods: Randomized, double-blind, crossover clinical trial comparing caffeine and placebo in moderate to severe depressed patients who underwent total sleep deprivation (SD). The patients were assessed with items of the Bond-Lader Scale, the 6-item Hamilton Depression Rating Scale (HAMD-6), and the Clinical Global Impression (CGI)-Severity/Improvement. Results: Twenty patients participated in this study. The patients who consumed caffeine presented the same score of energy before and after sleep deprivation (lethargicenergetic item of the Bond-Lader scale), while the patients in the placebo group had a reduced score of energy after sleep deprivation (p = 0.0045). There was no difference between the caffeine and placebo groups in the other items of the Bond-Lader scale. Conclusion: The combined use of caffeine and SD can be a useful strategy to keep the 12 patient awake without impairing the effect of SD on depressed outpatients. However, further studies involving patients who have responded to SD are needed in order to verify if caffeine also does not interfere with the results in this group.

Introdução: A privação de sono (PdS) tem sido utilizada como um estratégia alternativa para o tratamento do Transtorno Depressivo Maior (TDM), contudo sua eficácia e efetividade carecem de estudos homogêneos e de bom delinemento para dar um grau de evidência científica para seu uso na prática diária. Assim sendo, desde a primeira publicação, em 1971, num relato de caso de um paciente com TDM grave tipo melancólico, por Plug e Tölle, o mesmo estava assintomático no dia seguinte à privação total de sono. Contudo, na noite seguinte de sono seus sintomas depressivos retornaram. Nestes quase 40 anos desde esta publicação houve dezenas de estudos em sua maioria relatos de caso, série de casos ou até estudos abertos só que misturando pacientes com TDM com Depressão Bipolar sem mesmo distinguir se tipo I ou II. A cafeína com seu efeito estimulador poderia ser uma alternativa para facilitar a privação de sono. No entanto, não há dados sobre o sua potencial influência no efeito antidepressivo da PdS. O objetivo deste estudo é avaliar o efeito da cafeína na PdS em pacientes deprimidos unipolares moderados a graves não psicóticos. Métodos: Ensaio Clínico randomizado, duplo cego, cruzado, comparando cafeína contra placebo em pacientes deprimidos moderados a graves submetidos à privação total de sono (PdS). Os pacientes foram avaliados por itens da escala de Lader, HAMD- 6 itens, CGI Severidade e Melhora Global. Resultados: Foram avaliados 20 pacientes. Os pacientes que usaram cafeína mantiveram o mesmo escore de energia pré e pós-privação de sono (item energético-letárgico da escala de Lader) enquanto os do grupo placebo diminuíram o escore de energia pós-privação de sono. (p = 0,0045). Não houve diferença entre o grupo cafeína e placebo nos demais itens da escala de Lader. Conclusão: O uso combinado de cafeína e PdS pode ser uma estratégia útil para manter os pacientes mais acordados sem o prejuízo do cansaço da PdS em pacientes ambulatoriais deprimidos. Contudo, mais estudos envolvendo pacientes que tenham 10 respondido à PdS são necessários para verificar se a cafeína também não interfere nos resultados deste grupo. / Introduction: Sleep deprivation (SD) has been used as an alternative approach to treat major depressive disorder (MDD), however the efficacy and the effectiveness needs studies with homogeneity and better delineament to strengthen the evidence based medicine to the use in the practical daily use. Besides, since the 1° puplication in 1971 of a case report, by Plug and Tölle, in that one patient with severe melancholic depressive disorder achieved remission in the next day after a total sleep deprivation. However his depressive sintomtology was back after the next night of sleep. Since this almost 40 years, a lot of papers were puplished, and the majority where case report, case reports and open trials with patients with MDD, bipolar depression without make difference between tipe I or II. Caffeine, due to its stimulating effect, could be an alternative to promote sleep deprivation. However, there are no data about its potential influence on the antidepressive effect of SD. The objective of this study is to assess the effect of caffeine on SD in non-psychotic patients with moderate to severe unipolar depression. Methods: Randomized, double-blind, crossover clinical trial comparing caffeine and placebo in moderate to severe depressed patients who underwent total sleep deprivation (SD). The patients were assessed with items of the Bond-Lader Scale, the 6-item Hamilton Depression Rating Scale (HAMD-6), and the Clinical Global Impression (CGI)-Severity/Improvement. Results: Twenty patients participated in this study. The patients who consumed caffeine presented the same score of energy before and after sleep deprivation (lethargicenergetic item of the Bond-Lader scale), while the patients in the placebo group had a reduced score of energy after sleep deprivation (p = 0.0045). There was no difference between the caffeine and placebo groups in the other items of the Bond-Lader scale. Conclusion: The combined use of caffeine and SD can be a useful strategy to keep the 12 patient awake without impairing the effect of SD on depressed outpatients. However, further studies involving patients who have responded to SD are needed in order to verify if caffeine also does not interfere with the results in this group.

Abstract Depression, anxiety and sleep disorders have been reported to be associated with low level of inflammation, i.e., low-grade inflammation, but mainly in males. The evidence has mainly been based on laboratory or clinical studies with small sample sizes or epidemiological studies with elderly subpopulations. In this study the association of low-grade inflammation with depression, anxiety, and sleep disturbances was investigated using the Northern Finland 1966 Birth Cohort (NFBC 1966). In women, the effect of hormonal factors, menopause and the use of oral contraceptives/hormone replacement therapy on the association between low-grade inflammation and depression was also studied by using the Pieksämäki Study data. In 31-year follow-up of NFBC 1966 (N=6007), the depressive and anxiety symptoms were assessed by Hopkins Symptom Checklist-25 (HSCL-25) and sleep disorders by 15-D questionnaires, while the marker of low-grade inflammation, plasma concentration of high sensitivity C-reactive protein (hs-CRP), was measured. In the Pieksämäki study a representative sample of inhabitants in the town of Pieksämäki were invited to clinical examination. Depressive symptoms were obtained by Beck’s Depression Inventory-21, and hs-CRP was measured (512 women). The results of this study revealed that at epidemiological level, elevated hs CRP levels of ≥1.0 mg/L increased the probability of current depressive symptoms of single depressive episode in the two highest subgroups (i.e., HSCL-25 mean scores ≥1.75 and ≥2.01) 1.4- and 1.7- fold in males, respectively. In addition, anxiety symptoms (HSCL-25 anxiety scale mean score ≥1.75) increased independently the probability of elevated hs-CRP levels (>3.0 mg/L) in males over 2-fold. Risk ratio of 1.3 was found for males with moderate to severe sleep disturbances and elevated hs-CRP levels (≥1.0 mg/L). Regarding females, a positive correlation between elevated hs-CRP levels and depressive symptoms was found only among peri- and postmenopausal women not using exogenous hormones. The results suggest that low-grade inflammation is associated not only with depression but also with anxiety and sleep disturbances in young adult men. In women, hormonal factors may have an effect on the association between low-grade inflammation and depression. Further investigations are called for to confirm these findings and furthermore, to determine the possible role of low-grade inflammation in the pathophysiology of these disorders. / Tiivistelmä Depressio, ahdistuneisuushäiriöt ja unihäiriöt on yhdistetty elimistön matala-asteiseen tulehdustilaan, joskin pääasiallisesti vain miehillä. Tulosten yleistettävyyttä ovat rajoittaneet tutkimusten pienet otoskoot tai painottuminen iäkkäisiin väestöaineistoihin. Tässä tutkimuksessa selvitettiin matala-asteisen tulehduksen yhteyttä depressioon, ahdistuneisuuteen ja unihäiriöihin Pohjois-Suomen syntymäkohortti 1966 -aineistossa. Lisäksi Pieksämäki-tutkimuksen aineistossa selvitettiin naisilla menopaussin ja ehkäisyvalmisteiden/vaihdevuosihormonikorvaushoidon vaikutusta depression ja matala-asteisen tulehduksen väliseen yhteyteen. Pohjois-Suomen syntymäkohortti 1966 -tutkimuksen 31-vuotisseurannassa kartoitettiin 6007 henkilöltä masennus- ja ahdistuneisuusoireita Hopkins Symptom Checklist-25 -arviointiasteikolla (HSCL-25) ja unihäiriöitä 15-D-kyselyllä. Lisäksi mitattiin matala-asteisen tulehduksen mittarina käytetyn herkän C-reaktiivisen proteiinin (CRP) pitoisuus. Pieksämäki-tutkimuksessa edustava otos Pieksämäen asukkaista kutsuttiin kliiniseen tutkimukseen ja depressiivisiä oireita kartoitettiin Beckin 21-osioisella arviointiasteikolla ja mitattiin herkkä CRP (512 naista). Nuorilla aikuisilla miehillä, joiden herkkä CRP oli kohonnut (≥1.0 mg/l), todettiin 1.7-kertainen masennusoireiden riski, kun katkaisupisteenä käytettiin HSCL-25-kyselyn masennuskeskiarvopistettä ≥2.01. Ahdistuneisuusoireet (HSCL-25-kyselyn ahdistuneisuuskeskiarvopisteet ≥1.75) lisäsivät kohonneen herkän CRP:n riskiä (>3.0 mg/l) yli kaksinkertaiseksi miehillä. Keskivaikeasta tai vaikeasta unihäiriöstä kärsivillä todettiin 1.3-kertainen kohonneen herkän CRP:n (≥1.0 mg/l) riski. Naisilla positiivinen yhteys masennuksen ja kohonneen herkän CRP:n välillä todettiin vain peri- ja postmenopausaalisilla naisilla, jotka eivät käyttäneet hormonikorvaushoitoa tai suun kautta otettavia ehkäisyvalmisteita. Tutkimustulokset viittaavat matala-asteisen tulehduksen liittyvän depressioon, ahdistukseen ja unihäiriöön nuorilla aikuisilla miehillä. Naisilla hormonaaliset seikat mahdollisesti vaikuttavat depression ja matala-asteisen tulehduksen väliseen yhteyteen. Tulevaisuuden tutkimushaasteena on selvittää matala-asteisen inflammaation mahdollinen merkitys depression, ahdistuneisuuden ja unihäiriöiden patofysiologiassa.

The purpose of this study was to evaluate the effectiveness of a new anxiety prevention program, the Parent Resilience Program. The program is a cognitive-behavioral based prevention program designed to reduce the risk of anxiety in young children, specifically by reducing parent stress and teaching coping skills. The sample consisted of the parents and/or caregivers of 12 preschool-aged children. Parents attended eight weekly sessions of a psychologist-led intervention. Significant reductions were observed related to the impact of shyness on the child’s quality of life as well as parental anxiety and stress, both of which are risk factors for developing an anxiety disorder. In line with this, trends toward reduction were also seen in child anxiety symptoms and behavioral inhibition. These preliminary results suggest that the Parent Resilience Program may be effective at reducing the risk factors associated with the development of anxiety disorders.